PlasmaGen raises ₹150 crore, valuation crosses ₹1,500 crore
In a significant development in the Indian biotechnology sector, Bengaluru-based PlasmaGen Biosciences has raised ₹150 crore in a funding round led by ViNS Bioproducts. This investment has propelled the company’s valuation to over ₹1,500 crore, cementing its position as a leading player in the industry. With this funding, PlasmaGen has now raised over ₹600 crore to date, backed by prominent investors such as Eight Roads, FIL Capital, and F-Prime.
PlasmaGen Biosciences operates one of India’s five plasma fractionation facilities near Bengaluru, which is a critical component in the production of life-saving therapies. The company’s facility is equipped with state-of-the-art technology, enabling it to produce high-quality plasma-derived products that cater to the growing demand in the domestic and international markets.
The latest funding round is a testament to the company’s growth potential and the confidence that investors have in its capabilities. ViNS Bioproducts, the lead investor in this round, is a well-established player in the biotechnology sector, and its investment in PlasmaGen is expected to accelerate the company’s expansion plans.
PlasmaGen’s products portfolio includes a range of plasma-derived therapies, such as immunoglobulins, albumin, and clotting factors, which are used to treat various medical conditions, including immune system disorders, bleeding disorders, and liver diseases. The company’s products are manufactured in compliance with international quality standards, ensuring their safety and efficacy.
The Indian biotechnology sector has been witnessing significant growth in recent years, driven by government initiatives, increasing demand for healthcare services, and a growing pool of skilled professionals. The sector has attracted significant investments from both domestic and international investors, with many companies scaling up their operations to cater to the growing demand.
PlasmaGen’s success story is a reflection of the sector’s growth potential. The company’s ability to raise significant funding from prominent investors is a testament to its strong business model, experienced management team, and commitment to quality. With a strong product portfolio, state-of-the-art manufacturing facility, and a growing customer base, PlasmaGen is well-positioned to capitalize on the growing demand for plasma-derived products.
The company’s plans to expand its operations and increase its production capacity are expected to be accelerated with the latest funding. PlasmaGen is likely to invest in new technologies, hire more skilled professionals, and enhance its marketing efforts to increase its market share. The company’s expansion plans are expected to create new job opportunities, contribute to the growth of the Indian economy, and increase the country’s exports of biotechnology products.
In conclusion, PlasmaGen’s ₹150 crore funding round is a significant development in the Indian biotechnology sector. The company’s valuation crossing ₹1,500 crore is a testament to its growth potential and the confidence that investors have in its capabilities. With a strong product portfolio, state-of-the-art manufacturing facility, and a growing customer base, PlasmaGen is well-positioned to capitalize on the growing demand for plasma-derived products. As the company expands its operations and increases its production capacity, it is expected to create new job opportunities, contribute to the growth of the Indian economy, and increase the country’s exports of biotechnology products.
Source:
https://ascendants.in/funding-feed/plasmagen-biosciences-raises-rs-150-cr/
About the Author
